Morning Trend | SUNSHINE PHARMA under pressure for a pullback, when will the oversold rebound window arrive?

On January 21st, Dongxing Pharmaceuticals (6887.HK) fluctuated weakly at a low level throughout the day, with sporadic buying and funds showing no signs of large-scale inflow, maintaining a strong wait-and-see atmosphere. The short-term MACD death cross pressure is significant, with green bars continuously extending. Although there is an oversold condition, the main funds have not shown clear buying actions. The entire biopharmaceutical sector has been dragged down by medical insurance centralized procurement and policy adjustments, leading to a significant decline in investment enthusiasm. Dongxing Pharmaceuticals also has no major clinical progress or large order announcements disclosed, and the sector's speculative points have cooled down from last year's highs. Strategic funds tend to favor short-term trading on intraday fluctuations, with no clear willingness to hold overnight positions, and market risk appetite continues to decline. 12.10 yuan has become a key observation point for the short term, and a volume drop below this level indicates that the bearish forces still have room for release. The intraday chart occasionally shows technical rebounds, but the trading volume has not effectively expanded, lacking sustained follow-up buying. In the overall weak pattern, the oversold rebound window still needs to wait for sector funds and industry event catalysts. In the short term, it is recommended to pay attention to sector fund dynamics, new drug research and development progress, and policy news. Before market sentiment repairs or event-driven signals appear, right-side traders should still prioritize safety margins to prevent additional losses from short-term abnormal fluctuations